Printer Friendly

Cardiac Biomarker Company Critical Diagnostics Completes Financing For Market Expansion.

SAN DIEGO -- Critical Diagnostics, makers of the Presage[R] ST2 Assay, today announced it has completed a private placement for an undisclosed amount of capital to expand its commercialization efforts in the U.S., Europe and the Asia Pacific regions.

"This will allow us to take full advantage of the rapidly growing demand for ST2," says David Geliebter, Chief Executive Officer of Critical Diagnostics. "Today we move a step closer to realizing our founding vision of building a leadership role in helping in the treatment and management of cardiovascular disease by offering innovative solutions that save and improve lives while reducing overall healthcare costs."

"Some 23 million people worldwide suffer from heart failure," notes James Snider, President of Critical Diagnostics. "It is the number one reason people aged 65 or older are hospitalized. More alarming, of all heart failure patients discharged from the hospital, one-quarter will be readmitted within 30 days. The Presage ST2 Assay is a non-invasive blood test that allows for the early identification of these high-risk patients. Using ST2 as part of a patient management program can reduce 30-day rehospitalization rates by 17.3% and also reduce 30-day mortality rates by 17.6%."

About Critical Diagnostics and ST2

Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases. The Presage ST2 Assay has been CE Marked and cleared by the US FDA for use in risk stratification with chronic heart failure patients.
COPYRIGHT 2013 Business Wire, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1U9CA
Date:Feb 25, 2013
Words:286
Previous Article:Greenway Receives NCQA Prevalidation with Industry-Leading 20.5 Auto Credit Points Toward PCMH 2011 Scoring.
Next Article:Solar America to Provide Solar Solutions to Housing Project in Guadalajara.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters